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M A J O R A R T I C L E
A Patient with Asymptomatic Severe Acute
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from the 2003–2004 Community Outbreak of SARS
in Guangzhou, China
Xiao-yan Che,1 Biao Di,2 Guo-ping Zhao,3 Ya-di Wang,1 Li-wen Qiu,1 Wei Hao,1 Ming Wang,2 Peng-zhe Qin,2
Yu-fei Liu,2 Kwok-hong Chan,4 Vincent C. C. Cheng,4 and Kwok-yung Yuen4
1Center of Laboratory, Zhujiang Hospital, Southern Medical University, and 2Center for Disease Control and Prevention of Guangzhou, Guangzhou,
3Laboratory of Disease and Health Genomics, Chinese National Human Genome Center at Shanghai, Shanghai, and 4Department of Microbiology,
The University of Hong Kong, Hong Kong Special Administrative Region, People’s Republic of China
An asymptomatic case of severe acute respiratory syndrome (SARS) occurred early in 2004, during a community
outbreak of SARS in Guangzhou, China. This was the first time that a case of asymptomatic SARS was noted
in an individual with antigenemia and seroconversion. The asymptomatic case patient and the second index
case patient with SARS in the 2003–2004 outbreak both worked in the same restaurant, where they served
palm civets, which were found to carry SARS-associated coronaviruses. Epidemiological information and
laboratory findings suggested that the findings for the patient with asymptomatic infection, together with the
findings from previously reported serological analyses of handlers of wild animals and the 4 index case patients
from the 2004 community outbreak, reflected a likely intermediate phase of animal-to-human transmission
of infection, rather than a case of human-to-human transmission. This intermediate phase may be a critical
stage for virus evolution and disease prevention.
After the announcement of the end of the severe acute
respiratory syndrome (SARS) epidemic on 5 July 2003,
4 new community-acquired cases of SARS were re-
ported between 16 December 2003 and 8 January 2004,
in Guangzhou City in the province of Guangdong,
China [1]. The genomic sequences of SARS-associated
coronavirus (SARS-CoV) isolates recovered from these
4 index case patients with SARS and from palm civets
that were associated with this SARS outbreak were
nearly identical. The results of phylogenetic analysis,
combined with epidemiological lineage information,
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suggested that SARS-CoV was reintroduced to humans
from animals [2, 3]. Although it was reported that none
of these patients were involved in the secondary spread
of symptomatic SARS-CoV infection [1], we describe
a patient with asymptomatic SARS-CoV infection who
was identified from 115 contacts of the index case pa-
tients in this community outbreak. This asymptomatic
case of SARS-CoV infection was confirmed by a sen-
sitive method of viral antigen detection and by sero-
logical tests. The asymptomatic case also highlights
some issues associated with disease prevention.
PATIENTS AND METHODS
The present study was performed retrospectively. Sev-
enteen serum specimens were collected from 4 index
case patients who exhibited recurrence of SARS with
laboratory-confirmed SARS-CoV infection in Guang-
zhou City, China, from 22 December 2003 through 30
January 2004. An additional 118 serum specimens were
collected from 115 contacts of the 4 index case patients
with SARS.
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To identify the nucleocapsid (N) protein of SARS-CoV in
serum specimens, 2 antigen-capture assays were performed: an
N antigen–capture ELISA and an N antigen–capture chemi-
luminescent immunoassay (CIA). The development of these 2
assays was based on the detection of 3 monoclonal antibodies
directed against the N protein of SARS-CoV, as described else-
where [4–6]. Serum IgG and IgM antibodies to SARS-CoV were
detected using commercially available indirect ELISA kits (BGI-
GBI; Biotech) according to the manufacturer’s instructions [6].
The sensitivity and specificity of ELISA for the detection of IgG
antibodies to SARS-CoV were 99%–100% and 89%–97.2%,
respectively, and the sensitivity and specificity of ELISA for the
detection of IgM antibodies to SARS-CoV were 89.8% and
97.6%, respectively [6–8]. An indirect immunofluorescent assay
(IFA) for the detection of IgG antibodies to SARS-CoV was
performed using a commercially available IFA kit (Euroim-
mun), according to the manufacturer’s instructions [9]. This
IFA has a specificity of 100% (with detection of IgG antibodies
to SARS-CoV in 200 healthy blood donors) and a sensitivity
of 97%–100% (with detection of IgG antibodies to SARS-CoV
in 150 serum specimens obtained, at least 10 days after the
onset of symptoms, from patients with SARS). In-house IFAs
for the detection of IgG specific to human coronaviruses 229E
and OC43 were performed as described by us elsewhere [10].
A microneutralization assay was performed according to pro-
cedures described elsewhere, with modifications [1]. In brief,
a 96-well microtiter plate that contained confluent fetal rhesus
kidney–4 cells in 100 mL of maintenance medium was prepared.
Two-fold dilutions of patient serum samples (50 mL), which
started at 1:10 and increased to 1:320, were premixed with 50
mL TCID50 of SARS-CoV (the HKU-39849 isolate) and were
incubated at 37C for 1.5 h. Then, 100 mL of the virus-serum
mixture was inoculated in duplicate wells with fetal rhesus kid-
ney–4 cells and was further incubated at 37C. A cytopathic
effect was observed at 72 and 96 h. The neutralization titer was
determined to be the reciprocal of the highest serum dilution
that produced 50% cytopathic effect on cells. A neutralizing
antibody titer of 10 was considered to be positive for SARS-
CoV.
RESULTS AND DISCUSSION
All serum specimens were tested for the N protein of SARS-
CoV by use of both N antigen–capture ELISA and N antigen–
capture CIA. The findings of these 2 assays had been validated
previously with the use of serum specimens obtained from
patients with serologically confirmed SARS, and the sensitivity
and specificity of the N antigen–capture ELISA were docu-
mented [4–6]. Although the characteristic of the N antigen–
capture CIA was shown to be equivalent to that of the N an-
tigen–capture ELISA (data not shown), the N antigen–capture
CIA seemed to be more sensitive than N antigen–capture ELISA
in the present study. Both N antigen–capture assays detected
N protein in serially obtained serum specimens that were col-
lected from 3 patients 6–9 days after the onset of symptoms;
CIA was also able to detect N protein in serum samples collected
from the second index case patient on the ninth and 10th days
after the onset of symptoms, although these samples had neg-
ative results according to the N antigen–capture ELISA (table
1). This result was not surprising, because enzyme-amplified
chemiluminescent chemical analysis is generally more sensitive
than conventional ELISA [11]. For index case patient 4, the
first serum sample was obtained on day 17 after the onset of
symptoms, and N protein was not detectable in serially obtained
serum specimens during this patient’s illness.
Of the 118 serum specimens obtained from the 115 contacts
of the index case patients, 1 specimen, which was collected on
6 January 2004, was from a female contact of the second index
case patient, who experienced onset of symptoms on 26 De-
cember 2003. This female contact was found to be positive for
the N protein by means of N antigen–capture CIA, and the
presence of SARS-CoV infection was further confirmed by se-
rological tests (table 2). IFA detected a 16-fold increase in the
SARS-CoV antibody titer in paired serum samples collected
over a 1-week period. IgM and IgG antibodies to SARS-CoV
were also detected by ELISA. Antibodies to SARS-CoV were
also detected in the convalescent-phase serum sample obtained
from this female contact case patient 12 weeks later, and the
results of the SARS-CoV microneutralization assay were also
found to be positive, with a titer of 20 determined for the
convalescent-phase serum sample obtained from this female
contact case patient. The serological results were verified by the
Center for Disease Control and Prevention of Guangzhou,
which is one of the SARS reference laboratories in China.
To exclude the possibility of a false-positive result, serum spec-
imens from the contact case patient were tested for antibodies
against the human coronaviruses 229E and OC43, by use of IFA.
Paired serum samples showed no increase in the titer of anti-
bodies to either 229E or OC43. These tests were also performed
for serially obtained serum specimens from the 4 index case
patients (table 1). Although the paired serum samples obtained
from the first and second index case patients did show an increase
in the titers of antibodies to 229E and OC43, no neutralizing
antibodies against 229E and OC43 were detected in these index
case patients during a previous study [1].
Although none of the 4 index case patients showed evidence
of secondary spread of the infection [1], the direct detection
of SARS-CoV N protein by the highly sensitive CIA, comple-
mented by the results of serologic tests, clearly demonstrated
that a fifth case of SARS-CoV infection occurred, although the
4 index cases occurred during the 2003–2004 community out-
break of SARS in China. On the other hand, because the contact
case patient did not show any signs or symptoms of respiratory
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Table 1. Results of detection of severe acute respiratory syndrome (SARS)–associated coronavirus (SARS-CoV)
nucleocapsid (N) antigen, antibodies to SARS-CoV, and antibodies to the human coronaviruses 229E and OC43 in
the 4 index case patients with SARS from the 2003–2004 outbreak in Guangzhou City, China.
Patient (SARS onset date),
day after onset of symptoms
Antibodies to SARS-CoV detected
SARS-CoV
N protein detected
By IFA,
IgG titera
By ELISA,
OD450 (ratio)
b
IgG antibody titera
determined by IFA
By CIA By ELISA IgM IgG For 229E For OC43
1 (16 Dec 2003)
6 + + 160 0.724 (1) 0.355 (1) 40 320
8   ND 1.416 (1.9) 0.843 (2.4) 80 ND
10   ND 1.193 (1.6) 0.924 (2.6) ND ND
12   640 1.193 (1.6) 0.873 (2.5) 160 2560
2 (26 Dec 2003)
6 + + !10 0.142 (1) 0.129 (1) 40 320
7 + + ND 0.050 (0.4) 0.031 (0.2) ND ND
8 + + 320 0.513 (3.6) 0.584 (4.5) ND ND
9 +  ND 0.675 (4.8) 0.727 (5.6) 80 640
10 +  ND 0.282 (2.0) 0.526 (4.1) ND ND
11   ND 0.721 (5.1) 0.568 (4.4) ND ND
12   1280 0.462 (3.3) 0.785 (6.1) 320 1280
3 (30 Dec 2003)
9 + + 640 0.387 (1) 0.665 (1) 160 320
10   ND 0.162 (0.4) ND 160 320
11   640 0.355 (0.9) 0.795 (1.2) 160 320
4 (8 Jan 2004)
16   640 1.433 (1) 0.593 (1) 80 320
17   ND 1.135 (0.8) 0.539 (0.9) ND ND
22   640 1.219 (0.9) 0.618 (1.0) 80 320
NOTE. CIA, chemiluminescent immunoassay; IFA, indirect immunofluorescent assay; ND, not done; OD, optical density measured
at 450 nm; +, positive result; , negative result.
a Serum samples in a serial 2-fold dilution (from 10-fold to 5120-fold).
b The highest ratio of acute-phase to convalescent-phase absorbance values at the same serum dilution tested.
illness, her case is the first confirmed and documented asymp-
tomatic case of SARS in this outbreak.
This asymptomatic case of infection occurred in a 31-year-old
woman who was working as a service chief in the local restaurant
TDLR [2], where the second index case patient worked as a
waitress [2, 3]. Although the asymptomatic case patient had only
indirect contact with the second index case patient, she had a
history of clear and close animal (i.e., palm civet) contact. She
often showed the wild animals to customers who were ordering
exotic food. Subsequently, SARS-CoV N protein was detected,
by use of N antigen–capture ELISA, in 5 of a total of 6 palm
civet serum samples obtained during the same period from the
restaurant TDLR; results revealed a high level of N protein, with
a mean OD450 value of 1.556, compared with the cutoff value of
0.21. Viral RNA was also detected in all throat and rectal swab
specimens obtained from 6 palm civets, by use of RT-PCR for
the detection of polyprotein and N genes of SARS-CoV, and 3
full genome sequences and 2 complete S gene sequences of SARS-
CoV were identified in the specimens obtained from 5 of 6 palm
civets [3]. When this information is considered together with the
viral genomic information from the palm civets that was collected
from the same restaurant during the same period [2–3], the clear
conclusion is that the palm civets used for exotic food in the
restaurant must have been heavily contaminated with SARS-CoV.
With the limited samples available, the kinematics of the
antigenemia and antibody responses of the second index case
patient were compared with those of the asymptomatic case
patient. The asymptomatic case patient had antigenemia (i.e.,
detection of N antigen in serum; antigenemia was detected in
the asymptomatic case patient on 6 January 2004) disappear
at almost the same time as it disappeared in the second index
case patient (who had detectable antigenemia up to 5 January
2004). Meanwhile, the second index case patient had serocon-
version occur on 3 January 2004, whereas the asymptomatic
case patient had a positive antibody result from 6 January 2004;
however, because serum samples were unavailable before this
date, the exact date of seroconversion cannot be determined.
Nevertheless, because the mean incubation period for SARS is
6 days [12], it seems that the asymptomatic case patient was
unlikely to have acquired infection directly from the second
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Table 2. Results of detection of severe acute respiratory syndrome (SARS)–associated coronavirus (SARS-CoV)
nucleocapsid (N) antigen, antibodies to SARS-CoV, and antibodies to human coronaviruses 229E and OC43 in a
patient with an asymptomatic case of SARS in the 2003–2004 community outbreak of SARS in Guangzhou City,
China.
Date of serum
sample collection
Antibodies to SARS-CoV detected
SARS-CoV N
protein detected
By IFA,
IgG titera
By NA,
titer
By ELISA,
OD450 (ratio)
b
IgG antibody titera
detected by IFA
By CIA By ELISA IgM IgG For 229E For OC43
6 Jan 2004 +  80 ND 0.031 (1) 0.74 (1) 160 320
9 Jan 2004   640 ND 0.38 (12) 0.773 (1.0) 160 320
13 Jan 2004   1280 ND 1.451 (47) 0.801 (1.1) 160 320
24 Mar 2004   640 20 0.044 (1.3) 1.08 (1.5) 160 320
NOTE. CIA, chemiluminescent immunoassay; IFA, indirect immunofluorescent assay; NA, neutralization assay; ND, not done; OD450,
optical density measured at 450 nm; +, positive result; , negative result.
a Serum samples in a serial 2-fold dilution (from 10-fold to 5120-fold).
b The highest ratio of acute-phase to convalescent-phase absorbance values at the same serum dilution tested.
index case patient. Combining the epidemiological information
regarding the contact history with the molecular diagnostic
profiling of either the animals (the palm civets) or the human
(the second index case patient), we infer that this asymptomatic
case of SARS was more likely to have resulted from an animal-
to-human infection (likely due to SARS-CoV carried by the
palm civets from the restaurant) than from the second index
case patient.
SARS is a zoonotic disease. SARS-CoV evolved consistently
and rapidly within its animal and human hosts, while both the
infectivity of the virus and the severity of the disease varied,
along with the variation/adaptation of the virus to its hosts [2,
13]. It is particularly significant that even in the “early phase”
of the 2002–2003 SARS epidemic [13], human-to-human trans-
mission of infection was observed, and the symptoms were so
severe that the disease was eventually named after its primary
symptomatic characteristics. However, in the 2003–2004 com-
munity outbreak of SARS, none of the 4 index case patients
with confirmed SARS had severe illness, and they all seemed
to have acquired infection with SARS-CoV directly from ani-
mals. Although SARS-CoV–specific antibodies previously had
been detected at a relatively high rate among the population
handling wild animals or had been observed in health care
workers [14–16], it was impossible to correlate serological re-
sults with the corresponding onset of clinical symptoms in these
retrospective screenings. Therefore, the asymptomatic case pa-
tient described in the present article is the first patient with
asymptomatic SARS-CoV infection with detectable antigenemia
and seroconversion caused by animal-to-human infection.
This finding, together with the previously reported findings
of serological analysis of the handlers of wild animals and the
4 index case patients from the community outbreak of SARS
in 2004, reveals that there likely is an intermediate epidemio-
logical phase, which might be critical for genetic adaptation of
the virus to its new hosts before critical mutation enables it to
eventually cause severe symptomatic SARS, as was seen in early
2003. Although it is usually difficult to observe the virus in the
intermediate phase, SARS-CoV is one of the rare viruses for
which both genotypes [2, 13] and the antigen/antibody cor-
responding to the intermediate phase were detected.
This finding may also be significant for the prevention of
SARS epidemics. Although the most contagious human epi-
demic strain of SARS-CoV from the middle and late phases of
the 2002–2003 pandemic has not been seen in nature since
June 2003 [13], the risk of asymptomatic or mildly symptomatic
infection with SARS-CoV should not be ignored. To date, mo-
lecular epidemiological data have indicated that, although it
might take decades for SARS-CoV to evolve into a contagious
strain for human infection, it would not be too difficult for
SARS-CoV to reach the stage in which it might cause infection
either without symptoms or with mild symptoms in humans.
This process could be accelerated if appropriate susceptible
animal hosts, such as palm civets, were largely present together
with the human population. On the other hand, if the high-
risk population with infection can be properly monitored at
the asymptomatic stage and the disease can be promptly con-
trolled at the mildly symptomatic stage (both objectives are
technically feasible now), future threats of a reemerging SARS
epidemic could be much lower than once was surmised.
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